1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
- 2017
-
Mark
The European Vasculitis Society 2016 Meeting Report
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
- 2010
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
-
Mark
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis
(
- Contribution to journal › Article
- 2009
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies
(
- Contribution to journal › Article